Issues surrounding MDI formulation development with non-CFC propellants.
Reformulation of metered-dose inhalers (MDIs) without the use of chlorofluorocarbon (CFC) propellants presents numerous obstacles because there are no alternative propellants that can serve as immediate replacements for pharmaceutical use.  Hydrofluorocarbons (HFCs), hydrochlorofluorocarbons (HCFCs) and hydrocarbons (HCs) are all under consideration as possible alternatives for CFC propellants.  However, no single propellant or combination of propellants has been identified with all of the physical-chemical properties of CFCs.  Based on their zero ozone depletion potentials, relatively low global warming potentials, non-flammabilities, densities, and vapor pressures, HFA-134a and HFA-227 are the most attractive replacement propellants identified to date.  Yet, their use in MDIs will still require:  (1) identification of a metering valve with propellant and formulation-compatible gaskets, (2) use of current suspending agents at levels much lower than in present MDIs or identification (and characterization) of new suspending agents, and (3) modification of existing manufacturing technologies.  Demonstration of acceptable final product stability, safety and efficacy will be necessary prior to submission to worldwide registration authorities.
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877.
M J
MJ
Kontny
G
G
Destefano
P D
PD
Jager
D P
DP
McNamara
J S
JS
Turi
L
L
Van Campen
D000280:Administration, Inhalation; D000335:Aerosol Propellants / Q000737:chemistry / Q000592:standards*; D004867:Equipment Design; D006801:Humans; D006845:Hydrocarbons, Fluorinated / Q000737:chemistry / Q000592:standards*; D009330:Nebulizers and Vaporizers / Q000592:standards*